Lipopolysaccharide induces the expression of prostaglandin H synthase-2 with subsequent production of PGE 2 in human microvascular endothelial cells. In order to investigate the signaling pathways that are involved in the LPS-induced production of PGE 2 , the roles of several second messenger systems in this process were evaluated. Treatment of human microvascular endothelial cells with the tyrosine kinase inhibitors herbimycin A and genistein significantly inhibited LPSmediated PGE 2 production. Western blotting demonstrated that LPS induced the phosphorylation of p42, p44 and p38 MAP kinases. Both PD98059, an inhibitor of p42 and p44 MAP kinase activation, and SB203580, an inhibitor of p38 MAP kinase, blocked LPS-induced PGE 2 production. Inhibition of PKC activity by staurosporine and GF109203X resulted in a potentiation of the LPS response. Treatment of the cells with SN50, an NF-κB inhibitor, resulted in inhibition of the LPS-mediated PGE 2 production. These results suggest that LPS induces PGE 2 production in human microvascular endothelial cells through sequential activation of tyrosine kinases, ERK and p38 MAP kinases and NF-κB. In addition, PKC activity exerts a feedback control of PGE 2 production in LPS-stimulated microvessel-derived endothelial cells.
INTRODUCTION
Lipopolysaccharide (LPS), a component of the cell wall of Gram-negative bacteria, interacts with diverse cells of the body to produce a wide range of effects including significant alterations of inflammatory and immune functions. During a bacterial infection, LPS is released into the tissue space and into the circulation where it can interact both directly and indirectly with cells of the host. Endothelial cells are one type of cell whose functions are significantly altered by LPS. The effects of LPS upon endothelial cells include increased adhesion molecule expression, 1 cytokine production, 2 eicosanoid production, 3 nitric oxide synthase expression 4 and disruption of endothelial cell monolayer integrity. 5 Of particular interest within the microcirculation is the fact that LPS increases the synthesis and release of prostaglandin E 2 . 3 PGE 2 is unique among prostaglandins in that it possesses immunosuppressive activities including the ability to inhibit T cell and B cell proliferation, 6 T cell and B cell activation 6, 7 and T cell production of cytokines such as IL-4, IL-5, and IFN-γ. 8 It also inhibits phagocytosis by macrophages 9 and enzyme release, chemotaxis, and oxygen radical production by neutrophils. 10 Because of its ability to suppress immune function, the release of PGE 2 by endothelial cells in the midst of a bacterial infection could be detrimental and contribute to the further development of the shock state. Microvascular endothelial cells are in a prime location to release substances directly into the blood and lymph where they can interact with many cell types and exert widespread paracrine effects. Thus, the mechanisms by which LPS enhances PGE 2 production and release by this cell type is of potential clinical importance.
The general mechanism by which LPS induces the production of PGE 2 in microvascular endothelial cells has been determined. LPS causes the increased transcription of mRNA for prostaglandin H synthase 2 (PGHS-2) and cytoplasmic phospholipase A 2 (cPLA 2 ). 11 The induction of these enzymes occurs over a finite and reproducible period of time in vitro. There are several possible mechanisms by which this LPS-mediated induction of the eicosanoid-forming enzymes can be achieved. Numerous investigators have demonstrated that LPS can activate several forms of tyrosine kinases 12Ð17 and can also induce mitogen activated protein (MAP) kinase activity in such cell types as macrophages and monocytes. 18, 19 In addition, the overexpression of ERK 1 (p44 kinase) or ERK 2 (p42 kinase) mitogen-activated kinases has been shown to cause enhanced expression of the murine PGHS-2 gene 20 while activation of p38 MAP kinase has been shown to induce PGHS-2 expression in rat mesangial cells, 21 human monocytes 22 and human fibroblasts and HUVEC cells. 23 Another possible signal transduction pathway involved in LPS-mediated eicosanoid formation is protein kinase C (PKC). 18, 24, 25 Although these signal transduction pathways have been implicated in lipopolysaccharide-mediated effects on several biological systems in several types of cells, the specific signal transduction pathway(s) for LPSmediated eicosanoid effects in human microvascular endothelial cells has/have not been elucidated.
In the present study, the involvement of the above described signaling systems in the LPS-induced production of PGE 2 in human microvascular endothelial cells was examined. The functional roles of tyrosine kinase, MAP kinase and PKC activities in LPS-induced PGE 2 production are pharmacologically demonstrated as well as the involvement of the nuclear transcription factor, NF-κB.
MATERIALS AND METHODS

Materials
RPMI 1640 medium (powder), DulbeccoÕs phosphatebuffered saline (PBS), sodium bicarbonate, penicillin G, streptomycin, amphotericin B, bovine serum albumin (BSA), porcine heparin, FITC-labeled rabbit anti-goat IgG, arachidonic acid and leupeptin were purchased from Sigma Chemical Company (St Louis, MO, USA). Antisera to factor VIII-related antigen was purchased from Atlantic Antibodies (Stillwater, MN, USA). Collagenase, type I, was purchased from Worthington Biochemical Corporation (Freehold, NJ, USA). Percoll was purchased from Pharmacia (Piscataway, NJ, USA). Acetylated-low density lipoprotein labeled with 1,1′-dioctadecyl-1-3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate (DiI-Ac-LDL) was purchased from Biomedical Technologies Inc. (Stoughton, MA, USA). Defined fetal bovine serum (FBS) was obtained from Hyclone Laboratories, Inc. (Logan, UT, USA). Non-fat powdered milk was purchased from ALBA. Purified LPS (Escherichia coli O111:B4) was purchased from List Biological Laboratories, Inc. (Campbell, CA, USA). Endothelial cell growth supplement (ECGS) was prepared following the method of Maciag et al. 26 from bovine hypothalami which were purchased from PEL-Freeze Biologicals (Rogers, AR, USA). [ 3 H]-PGE 2 was purchased from New England Nuclear (Boston, MA, USA). Polyclonal antisera directed against PGE 2 was prepared in our laboratory as described by Renzi and Flynn. 3 Staurosporine, genistein and herbimycin A were purchased from LC Laboratories (Woburn, MA, USA). GF109203X, PD98059, and SN50 were purchased from BIOMOL (Plymouth Meeting, PA, USA). A PhosphoPlus MAPK Antibody Kit and a PhosphoPlus p38 MAP Kinase (Thr180/Tyr182) Antibody Kit were purchased from New England Biolabs (Beverly, MA, USA).
Endothelial cell isolation and culture
Primary cultures of microvascular endothelial cells from human perirenal adipose tissue were isolated as previously described. 3 The human fat was obtained with informed written consent from the donor during livingrelated donor renal transplant procedures performed at Thomas Jefferson University Hospital. The Thomas Jefferson University Institutional Review Board approved all protocols. Following isolation and purification, the cells were placed in RPMI-1640 medium containing 10% FBS, 15 mM HEPES (pH 7.4), 100 µg/ml streptomycin, 125 µg/ml penicillin, 3.5 µg/ml amphotericin B, 1 µM arachidonic acid, 100 µg/ml heparin, and 100-150 µg/ml of endothelial cell growth supplement. The cells were then plated in 6-well tissue culture plates (9.6 cm 2 per well) which had been previously coated with a 1% gelatin solution. The cells were plated at a density of 250,000 particles per well (as determined with a Coulter counter) and were placed in an incubator at 37¡C with humidified air and 5% CO 2 . After 90 min incubation had elapsed, the medium was aspirated and the wells were washed with PBS containing 0.2% bovine albumin to remove any debris and non-adherent cells such as erythrocytes, smooth muscle cells or pericytes. Normally, about 70,000 cells remained adherent after this wash. Each well then received 2 ml of the RPMI-1640 medium described above and the culture was allowed to grow until ready for experimentation. In some cases, the cells were plated in 1% gelatin precoated 75 cm 2 tissue culture flasks. The cells were plated at a density of 2 x 10 6 particles per flask. Cells prepared in this way tested positive for DiI acetylated LDL uptake after 4 h and also stained positive for factor VIII-related antigen.
Additional cultures of human microvascular endothelial cells were used that were transformed with the gene encoding the SV40 large T antigen to create an immortalized cell line as described by Flynn et al. 27 These cells, termed HADMEC-5, have been extensively characterized and have been shown to retain the ability to internalize acetylated LDL and to express factor VIII-related antigen. HADMEC-5 cells also retain the ability to respond to picogram quantities of LPS with the production of significant amounts of PGE 2 . This cell line is available from our laboratory but has not been tested for the presence of mycoplasmal contamination.
Radioimmunoassay
In order to determine the quantity of prostaglandin E 2 released by the monolayer of cells into the culture medium, the medium was aspirated from the cells and a radioimmunoassay was performed using rabbit antisera directed against PGE 2 . The antibodies were previously produced in our laboratory. The procedure is fully described by Renzi and Flynn. 3 A 100 µl aliquot of the medium was assayed and all samples were run in duplicate.
Electrophoresis of proteins
Endothelial cell samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) prior to transfer to polyvinylidene fluoride membranes (PVDF) and Western blotting procedures. Protein determinations were performed on the cell extracts using the enhanced protocol of a BCA (bicinchoninic acid) Protein Assay Kit (Pierce Chemical Company, Rockville, IL, USA). Samples (10 µg) in SDS sample buffer were heated at 100¡C for 3 min and were then applied to a polyacrylamide gel consisting of a 5% stacking gel and a 9% separating gel. The gel was subjected to electrophoresis with a voltage of 200 V for 45 min. The samples were transferred to PVDF membranes purchased from Micron Separations Inc. (Westborough, MA, USA).
Western blotting
PVDF membranes were subjected to Western blotting procedures in order to assess the phosphorylation state of the p44 (ERK 1), p42 (ERK 2) and p38 MAP kinases using phospho-specific MAPK antibodies. The membranes were washed once in Tris-buffered saline (TBS) prior to a 3 h incubation in blocking buffer. The blocking buffer used was TBS containing 5% milk and 0.1% Tween 20. The membranes were then incubated overnight at 4¡C in a 1:1000 dilution of the phospho-specific MAPK antibody prepared in TBS with 5% BSA and 0.1% Tween 20. The membranes were then washed 3 times for 5 min each in TBS with 0.1% Tween 20. This step was followed by a 1 h incubation in the secondary antibody solution which contained two antibodies diluted in the blocking buffer. The two antibodies used were a horseradish peroxidase (HRP) conjugated antirabbit antibody at a dilution of 1:2000 and a HRP-conjugated anti-biotin antibody at a dilution of 1:1000. After the 1 h incubation, the membranes were washed 3 times for 5 min each in TBS with 0.1% Tween 20. Chemiluminescence was used to visualize the antibodies. The membranes were incubated for 1 min in the LumiGLOc hemiluminescence reagent provided with the kit and were then exposed to Reflectionª autoradiography film (Dupont NENª Research Products, Boston, MA, USA) for varying amounts of time to allow optimal visualization of the bands. Appropriate standards were included in the experimental procedures.
Signal transduction inhibitor studies
A series of experiments were carried out utilizing inhibitors of tyrosine kinase, protein kinase C, MAP kinase, and NF-κB in an effort to determine whether a particular mediator was involved in the LPS induction of PGE 2 production. The cells were pretreated with the appropriate inhibitor prior to the addition of LPS and then were incubated in the presence of both LPS and the inhibitor. Inhibitor concentrations and pre-incubation times were selected based upon a review of the pertinent literature. The effect of the inhibitor on the LPS-mediated eicosanoid response of the cells was evaluated.
For all experiments in this series of inhibitor studies, the basic protocol remained constant. Cells were grown in 6-well tissue culture dishes which had been precoated with 1% gelatin. Primary cultures of microvascular endothelial cells (HMEC) were grown in RPMI-1640 with 10% FBS, antibiotics, 1 µM arachidonic acid, endothelial cell growth supplement and heparin. The transformed HADMEC-5 cells at passage numbers 7 through 14 were grown in RPMI-1640 with 5% FBS, antibiotics, and 1 µM arachidonic acid. Arachidonic acid was added to the medium to provide the growing cells with this essential fatty acid. This ensured that the cells contained sufficient substrate for eicosanoid production. At the time of experimentation, the treatment medium contained no arachidonic acid. The cells were grown until they approached confluence as determined by visual inspection. At this point, the medium was aspirated and 900 µl of fresh dosing medium was added to the cells. The dosing medium used was always RPMI-1640 medium with 5% FBS and antibiotics with no other additives. The dosing medium contained the inhibitor being studied at various concentrations or vehicle alone for control cells. The vehicle for all inhibitor compounds was DMSO with the exception of SN50 whose vehicle was dH 2 0. The cells were incubated for the designated pretreatment time to pretreat the cells with inhibitor prior to the addition of LPS. At the end of the pretreatment period, LPS was added to the medium in all wells except the control cells and gently rocked to ensure complete mixing. The concentration of LPS for all inhibitor studies was 10 ng/ml. The cells were incubated for 20 h, after which time, the medium was collected for PGE 2 analysis by RIA and a cell count was performed.
MAP kinase phosphorylation studies
HADMEC-5 cells at passage 14 were plated onto 1% gelatin precoated 100 mm culture dishes and were grown in the standard growth medium for HADMEC-5 cells. The cells were used for experimentation when they reached a state of near confluence. Sixteen hours prior to the start of the experiment, the medium was aspirated from the cells and 3 ml of fresh growth medium were added. At time zero, 100 µl of medium which contained either LPS or vehicle alone were added to the cells, and the dishes were gently rocked to ensure thorough mixing. The LPS-treated groups received 750 ng of LPS for a final concentration of 250 ng/ml in the culture dish. Prior studies in these cells demonstrated that this dose produced a maximal eicosanoid response but did not adversely affect cellular function. The cells were incubated for 1, 5, 10, 20, 30 and 45 min in the presence of either LPS or drug vehicle. Following the incubation, the medium was aspirated from the cells and the cells were washed once with PBS. Then, 250 µl of cold lysis buffer were added to the cells and the dishes were quickly placed on ice. The lysis buffer contained 1% Triton X-100, 10 mM Tris, 50 mM NaCl, 3 mM sodium pyrophosphate, 50 mM NaF, 1 mM vanadate, and 1 mM PMSF. The surface of the culture dishes was scraped with a rubber policeman to remove the cells and place them into suspension. The cell lysate was kept on ice for 15 min and was then centrifuged for 15 min at 10,400 g. The supernatant was collected, and a protein determination was performed. The samples were subjected to SDS-PAGE and Western blotting using antibodies that specifically recognize the phosphorylated species of ERK 1/ERK 2 MAP kinases or p38 MAP kinase. The phosphorylated state of these enzymes is the activated state. Therefore, the amount of active kinase present can be determined with these phospho-specific antibodies. These experiments were repeated 4 times for the ERK kinase study and 3 times for the p38 kinase study.
In order to evaluate the effect of the MEK inhibitor PD98059 on the phosphorylation and activation of the p42 and p44 MAP kinases by LPS, HADMEC-5 cells were pretreated with PD98059 prior to stimulation with LPS. The protocol was identical, except that the cells were pretreated with PD98059 for 1 h prior to the addition of LPS. The cells were incubated for either 5 min or 30 min in the presence of LPS.
Statistical methods
The data are presented as the mean ± SEM with n = the total number of observations collected within the study. An observation is considered to be one well of cells. Each experiment was usually repeated three or more times. Because HADMEC-5 is a cell line, repeated measures ANOVA was used to analyze the data. Repeated measures ANOVA calculates a Ôwithin subject errorÕ term as an appropriate measure of variability for assessing the treatment effects involving the repeated measure. All data were analyzed using Statview 4.5 (Abacus Concept, Inc., Berkeley, CA, USA), a commercially available statistical package. In order to determine significant differences between means, the values were compared using StudentÕs t-test modified for multiple comparisons following the repeated measures ANOVA. A 5% probability level (P < 0.05) was accepted as indicating a significant difference between mean values.
RESULTS
The effect of tyrosine kinase inhibitors on LPS-induced PGE 2 production in primary cultures of HADMEC-5 cells and HMEC cells
HADMEC-5 cells were pretreated with the tyrosine kinase inhibitor, herbimycin A, for a period of 4 h prior to the addition of LPS (10 ng/ml). One group was treated with only herbimycin A at a concentration of 200 nM (Fig. 1) . The mean value of the herbimycin alone group was not significantly different from that of the control group. The LPS alone group had a significantly increased PGE 2 mean value (9.7 ± 2.2 ng/10 6 cells/20 h) as compared to that of the control (2.2 ± 0.3 ng/10 6 cells/20 h) as well as the herbimycin A alone treated group (2.9 ± 0.4 ng/10 6 cells/20 h). The herbimycin A at all concentrations evaluated demonstrated a significant inhibition of the LPS-stimulated PGE 2 production.
In addition, HMEC cells were pretreated with genistein for 30 min prior to the addition of LPS (10 ng/ml) to the medium. Genistein is a tyrosine kinase inhibitor that exerts its effect by binding competitively at the ATP binding site. Genistein was found to inhibit the LPS-induced production of PGE 2 (Fig. 2) . The mean value of PGE 2 production for control cells which received only vehicle was 2.2 ± 0.3 ng/10 6 cells/20 h. The LPS-treated group had a PGE 2 value of 7.7 ± 0.6 ng/10 6 cells/20 h. Groups which received LPS and genistein at concentrations of 0.5, 5, and 50 µg/ml had PGE 2 values of 7.8 ± 0.6, 2.2 ± 0.4 and 1.9 ± 0.3 ng/10 6 cells/20 h respectively. The inhibition at concentrations of 5 and 50 µg/ml was statistically significant (P < 0.05). One group received genistein alone. The PGE 2 value in this group was 0.7 ± 0.1 ng/10 6 cells/20 h, a value that was not significantly different from that of the vehicle alone group. Thus, two inhibitors of tyrosine kinase provided significant inhibition of LPS-mediated PGE 2 production.
The effect of a MAP kinase inhibitor on LPS-induced PGE 2 production in HADMEC-5 cells
PD98059 is an inhibitor of MEK which results in inhibition of the ERK forms of MAP kinases. To determine if ERK was involved in the LPS-induced production of PGE 2 , HADMEC-5 cells (passage 14) were pretreated with five different concentrations of PD98059 for 60 min prior to the addition of LPS for a 20 h incubation (Fig. 3) . One group of cells received PD98059 alone at a concentration of 3 µM. This high dose of PD98059 causes a slight, but significant, increase in PGE 2 production (2.3 ± 0.6 ng/10 6 cells/20 h) as compared to the PGE 2 value of the time-matched control group (0.5 ± 0.1 ng/10 6 cells/20 h). The PGE 2 value of the LPS alone group (12.0 ± 1.9 ng/10 6 cells/20 h) was significantly greater than that of the control group value. PD98059 significantly inhibited the LPS-induced production of PGE 2 at all concentrations evaluated.
MAP kinase phosphorylation studies
The phosphorylation state of p44 (ERK 1) and p42 (ERK 2) MAP kinases, both pre-and post-LPS treatment, was evaluated using an antibody that is specific for the phosphorylated forms of p42 and p44. HAD-MEC-5 cells were treated with LPS (250 ng/ml) for various periods of time, and extracted proteins were subjected to Western blotting procedures. As shown in Figure 4A , the LPS treatment resulted in an increase in the degree of phosphorylation of the p42 kinase at all time points compared to time-matched controls. The LPS treatment also induced the phosphorylation of the p44 kinase at all time points, although the magnitude of the phosphorylation appeared to be less than that of the p42 kinase. The phosphorylation of both the p42 and p44 kinases at the 20, 30, and 45 min time points were decreased from the degrees of phosphorylation at the 1, 5, and 10 min time points in both unstimulated and LPSstimulated cells. The bands become somewhat faint at these later time points. However, a slight increase in the phosphorylation state of the LPS-treated cells is still detectable over that of the control cells at these later time periods. These results demonstrate that both p42 and p44 kinases are more phosphorylated after treatment with LPS. This increase in phosphorylation is rapid (1Ð10 min) and remains modestly elevated for at least a 45 min time period. These data demonstrate that the ERK kinases are significantly activated in vitro by LPS.
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To confirm these findings, another study was carried out. HADMEC-5 cells were pretreated with either vehicle or PD98059 at a concentration of 10 µM or 20 µM for 1 h prior to LPS treatment. The cells were then treated with either LPS (250 ng/ml) or vehicle alone for 5 or 30 min. Cell-associated protein was subjected to Western blotting. Cells which did not undergo a pretreatment with PD98059 demonstrated an increase in the amount of phosphorylation of both p42 and p44 proteins in response to LPS as compared to that of control group cells at both 5 and 30 min (Fig. 4B) . Cells that were pretreated with PD98059 demonstrated a dramatic decrease in the amount of phosphorylation of both p42 and p44 after drug pretreatment. This was seen in both LPS-stimulated cells and in unstimulated cells at both 5 and 30 min. These data confirm that, at the concentrations and pretreatment time used in the previous PD98059 studies, PD98059 does in fact inhibit the phosphorylation and subsequent activation of the p42 and p44 kinases in our model.
The effect of a p38 MAP kinase inhibitor on LPSinduced PGE 2 production in HADMEC-5 cells
SB203580 is an inhibitor of the p38 MAP kinase. In order to determine whether p38 is involved in the LPSinduced production of PGE 2 , HADMEC-5 cells were pretreated with SB203580 for 60 min prior to the addition of 10 ng/ml LPS (Fig. 5 ). One group received 1 µM SB203580 alone. As expected, the mean PGE 2 value of the LPS-treated group (4.5 ± 0.3 ng/10 6 cells/20 h) was significantly greater than that of the control group (0.6 ± 0.1 ng/10 6 cells/20 h). SB203580 alone did not stimulate PGE 2 production (0.4 ± 0.1 ng/10 6 cells/20 h). SB203580 was able to significantly inhibit the LPS-induced production of PGE 2 at all concentrations evaluated. form of p38 MAP kinase. Treatment with LPS resulted in the phosphorylation of p38 at all time points evaluated, with a dramatic stimulation of p38 MAP kinase phosphorylation at 20, 30 and 45 min (Fig. 6 ).
The effect of protein kinase C inhibitors on LPSinduced PGE 2 production in HADMEC-5 cells
Staurosporine is an inhibitor of several kinases, but, at the concentrations used in this study, is specific for PKC. HADMEC-5 cells were pretreated with staurosporine for 30 min before the addition of 10 ng/ml LPS (Fig. 7) . One group of cells received only staurosporine at a concentration of 1.5 nM and demonstrated a PGE 2 production rate (0.4 ± 0.1 ng/10 6 cells/20 h) that was indistinguishable from that of the control group (0.5 ± 0.1 ng/10 6 cells/20 h). Treatment with LPS resulted in a significant increase in PGE 2 production to approximately 10 times that of the control group rate (5.1 ± 0.2 ng/10 6 cells/20 h). In groups which received both LPS and staurosporine, staurosporine, in a concentration dependent manner, enhanced the production rate of PGE 2 over the rate measured in the LPS alone treated group. A significant increase in the PGE 2 production rate occurred at staurosporine concentrations of 0.38, 0.75, and 1.5 nM.
Bisindolylmaleimide I (GF-109203X) is a simplified synthetic derivative of staurosporine that possesses improved selectivity for PKC inhibition as compared to staurosporine. HADMEC-5 cells were pretreated with GF-109203X at a single concentration of 6 µM for 30 min prior to the addition of LPS (10 ng/ml). The GF-109203X potentiated the LPS response in these cells. Cells which received vehicle alone had a PGE 2 production rate of 0.4 ± 0.1 ng/10 6 cells/20 h. LPS treatment alone resulted in a PGE 2 production rate of 3.1 ± 0.2 ng/10 6 cells/20 h. In HADMEC-5 cells that were treated with LPS and GF109203X (6 µM), the rate of PGE 2 production was 4.0 ± 0.2 ng/10 6 cells/20 h which was significantly higher than that of the LPS treatment alone group. The control group PGE 2 production was not significantly different from that of the group which received GF-109203X alone (0.3 ± 0.1 ng PGE 2 /10 6 cells/20 h), while the LPS treatment alone group mean value was significantly different from those of the control and the GF-109203X alone group values (P < 0.05; n = 6). Thus, two different inhibitors of PKC activity were demonstrated to potentiate the LPS-mediated increase in the rate of PGE 2 production in human microvessel-derived endothelial cells.
The effect of an NF-κB inhibitor on LPS-induced PGE 2 production in HADMEC-5 cells
SN50 is an inhibitor of NF-κB activation which exerts its effect by interfering with the nuclear localization of NF-κB
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Fig. 6 Phosphorylation of p38 MAP kinase. HADMEC-5 cells were treated with either LPS (250 ng/ml) or vehicle for 1, 5, 10, 20, 30, or 45 min. Western blotting was performed using a phospho-specific MAP kinase antibody which recognizes the phosphorylated form of the kinase. The blot shown is representative of three experiments. Fig. 7 The effect of a protein kinase C inhibitor, staurosporine, on LPSinduced production of prostaglandin E 2 in HADMEC-5 cells. The cells were pretreated with staurosporine for 30 min prior to a 20 h incubation with LPS (10 ng/ml). Values are the mean ± SEM for 12 observations per group. (*P < 0.05 when compared to the LPS alone group value). components. HADMEC-5 cells were pretreated with SN50 for 15 min prior to a 20 h treatment with 10 ng/ml of LPS (Fig. 8 ). One group received SN50 (50 µM) alone. The production rate of PGE 2 in this group was significantly increased over that of the control group, but was still significantly lower than that of the group which received LPS alone. The three groups which received LPS (10 ng/ml) and SN50 at concentrations of 25, 50 and 100 µM had PGE 2 production that was significantly decreased from that of the LPS alone group. The SN50 inhibited the LPS-stimulated production of PGE 2 in the HADMEC-5 cells at these concentrations.
DISCUSSION
The interactions between bacterial lipopolysaccharides and the vascular endothelium are of great importance in the study of septic or endotoxic shock. LPS that is circulating within the vascular compartment is in direct contact with the endothelium. Because of their location, endothelial cells are in a position to release substances that can rapidly enter and travel through the blood and lymph systems having widespread effects. Endothelial cells derived from the microvasculature are distinctly different than large vessel-derived endothelial cells and respond differently to various stimuli, including LPS. 28 Taken as a whole, they constitute a mass of tissue within the body of approximately 1.5 kg. The en mass response of an organ system possessing such a large mass would have a rapid and significant impact upon various physiological processes. Among physiological mediators released by microvessel endothelial cells in response to LPS is PGE 2 . This eicosanoid is very important not only for its vasoactive properties but, more significantly, for its immunosuppressive characteristics. These include inhibition of T cell and B cell proliferation and activation and inhibition of macrophage and neutrophil activation. 6Ð9 PGE 2 -mediated alterations in immune function could have profound effects in the midst of a bacterial infection. The production of PGE 2 in vitro in response to clinically relevant concentrations of LPS is delayed, not immediate. A 20 h time course of PGE 2 production after treatment with LPS shows that human microvesselderived endothelial cells do not produce any PGE 2 until after 4 h, at which time there is a steady increase. 11 HAD-MEC-5 also responded to LPS in a similar manner. 27 These observations suggest that it is unlikely that LPS causes an increase in PGE 2 production by initiating a rapid burst-like increase in substrate availability as would occur with a Ca 2+ -mediated activation of cPLA 2 . On the contrary, the increased production of PGE 2 by the microvascular endothelial cell appears to be due to a mechanism that requires several hours to manifest its effect. Renzi and Flynn suggested that LPS-induced PGE 2 production was likely to be dependent upon synthesis of new protein, since cyclohexamide, an agent known to inhibit protein translation, abolished the production of PGE 2 in response to LPS. 3 A second possible explanation for time-dependent changes in eicosanoid production would be a slowly developing change in phospholipase A 2 activity. It has been shown that LPS can induce the activation of cPLA 2 by phosphorylation; 29 however, it would be likely that a phosphorylation-based mechanism would result in a more rapid increase in PGE 2 production than the 3Ð4 h time frame as seen in the current model after lipopolysaccharide treatment.
To define the mechanism by which LPS induces eicosanoid synthesis, we have previously demonstrated that LPS induces the transcription of PGHS-2 and cPLA 2 mRNA in human microvascular endothelial cells. 11 The increase in PGHS-2 mRNA begins at approximately 2 h, has a maximal peak at 4 h and then declines with another small peak at 12 h. The increase in PGHS-2 mRNA is in agreement with the time course of PGE 2 production. Thus, LPS interaction with the microvascular endothelium ultimately results in the increased transcription of message for the enzymes that are involved in eicosanoid formation.
The sets of experiments described in this report were designed to investigate the signal transduction pathway(s) by which LPS induces the enhanced transcription of PGHS-2 mRNA and subsequent production of PGE 2 in human microvessel-derived endothelial cells. A pharmacological approach using agents known to inhibit various signaling mediators was taken to ascertain which mediators may be involved in this pathway. It is important to note that, although these agents are known to inhibit particular signaling mediators, the possibility that these agents may have non-specific effects cannot be ruled out. Therefore, no absolute statement can be made regarding the involvement of the signaling mediators based solely on information obtained through the use of inhibitors. However, the data can suggest which mediators are likely to be involved.
LPS has been demonstrated, in several types of cells, to induce the tyrosine phosphorylation of various proteins. 12, 18, 19 Since tyrosine kinase activity has also been implicated in the induction of PHGS-2 and subsequent production of prostaglandins, 13Ð17,30 the involvement of tyrosine kinases in LPS-mediated PGE 2 production in microvascular endothelial cells was examined. In our studies, herbimycin A almost completely inhibited the LPS-mediated PGE 2 response under the conditions of our studies. Herbimycin A is a tyrosine kinase inhibitor that is more selective for the non-receptor src-related protein tyrosine kinases. 30, 31 In addition, genistein, which inhibits both receptor and non-receptor tyrosine kinases, was able to inhibit LPS-mediated PGE 2 production completely under the experimental conditions employed.
One possible method of signal transduction linking LPS to non-receptor tyrosine kinases has been suggested. Stevanova et al 32 showed that the protein tyrosine kinase p56 lyn can be coupled to the CD14 molecule in human monocytes. CD14 is a protein that is associated with the cellular membrane by a glycophosphatidylinositol (GPI) anchor. In order for LPS to be recognized on the surface of myeloid cells, it must bind to membrane bound CD14. Stevanova et al demonstrated co-immunoprecipitation of p53/56 lyn with CD14 from LPS-stimulated monocytes. Also, p53/56 lyn , as well as p58/64 hck and p59 fgr , which are also members of the src-related tyrosine kinase family, were activated upon stimulation of the monocytes with LPS. LPS-initiated activation of src-related tyrosine kinase activity has been demonstrated to lead to PGHS-2 expression. Treatment of rat macrophages with LPS stimulated tyrosine phosphorylation of p53/56 lyn and subsequent induction of PGHS-2 expression. 33 A number of secondary signaling pathways can be activated by enhanced tyrosine kinase activity. Among these, mitogen activated protein (MAP) kinases have been demonstrated to be activated downstream of tyrosine kinases, including the src-related tyrosine kinases. 34 Considering that MAP kinases have been shown to be activated during LPS treatment 12, 13, 18 and that they have been implicated in the induction of PGHS-2, 14,20 experiments were carried out to determine whether any members of the MAP kinase family were involved in the LPS signaling events in human microvascular endothelial cells that lead to PGE 2 production.
PD98059 is a selective inhibitor of MEK1, which is the kinase responsible for phosphorylating and activating the ERK 1 (p44) and ERK 2 (p42) members of the MAP kinase family. Our results confirm that PD98059 is acting in our model as a MEK1 inhibitor and that it blocks the activation of both ERK 1 and ERK 2. These data demonstrate that both ERK 1 and ERK 2 are activated upon stimulation with LPS in HADMEC-5 cells and suggest that this activation is a necessary event for subsequent PGE 2 production.
Another member of the MAP kinase family is a p38 MAP kinase which has also been shown to be activated upon treatment with LPS. 12, 13 Activation of p38 has been linked to the induction of PGHS-2 and subsequent production of prostaglandins in several cell types. 21, 22, 23 Also, p38 is activated downstream of Rac or Raf, which are activated by the src-related tyrosine kinases. Our studies demonstrate that p38 is activated by LPS in human microvascular endothelial cells and suggest that p38 is also involved in the LPS-induced production of PGE 2 .
Recently, in a study evaluating PGHS activity in human platelets, Bšrsch-Haubold et al demonstrated that PD98059 and SB203580 are capable of inhibiting PGHS-1 and PGHS-2. 35 The IC 50 for inhibition of PGHS-1 by PD98059 and SB203580 was 1 µM and 2 µM, respectively. The IC 50 for inhibition of PGHS-2 by PD98059 and SB203580 was 4 µM and 2 µM, respectively. These observations concerned us in that both systems (MAP kinases and PGHS) were functional in our model system. However, the concentrations of PD98059 and SB203580 which demonstrated significant inhibition of PGE 2 production in our studies are well below the IC 50 values that inhibit PGHS-2. We, therefore, assume that the mechanism of inhibition of PGE 2 production by PD98059 and SB203580 in our studies is through inhibition of ERK and p38 kinases and not through direct inhibition of PGHS-2.
The involvement of PKC activity in LPS-induced PGE 2 production was also examined. Staurosporine and GF-109203X both significantly potentiated LPS-elicited PGE 2 production under the conditions of these studies and did not affect basal PGE 2 production when added alone. One interpretation of these data is that PKC activity is involved in a pathway which is suppressing PGE 2 production. This activity is only prominent under conditions of LPS-stimulation and not during basal, non-stimulated conditions. This phenomenon has been observed elsewhere. In a study of rat mesangial cells, Rzymkiewicz et al demonstrated that an increase in PGHS-2 mRNA and PGE 2 production mediated by IL-1β could be potentiated by treatment of the cells with staurosporine. 25 The authors proposed that staurosporine may be inhibiting a PKC isoform that negatively regulates the transcription of PGHS-2 via activation of a phosphatase.
These studies suggest that bacterial lipopolysaccharides interact with human microvessel-derived endothelial cells in vitro to activate tyrosine kinase activity which leads to subsequent ERK and p38 MAP kinase activity. Both ERK and p38 appear to be directly involved in the signaling pathways initiated by treatment of the cells with LPS. Similar data have been observed in murine macrophages, where LPS-stimulated PGHS-2 induction involved activation of both the ERK and p38 kinases. 38 There are other observations demonstrating ERK and p38 kinases working in concert to induce transcription of both PGHS-2 and cytokines, such as IL-6 and TNF. These include IL-1β-stimulated induction of PGHS-2 in cardiac myocytes 39 and LPS-stimulated cytokine release in alveolar macrophages which both require ERK and p38 kinase activation. 40 The link between the ERK and p38 MAP kinase signaling pathways and the increased transcription of PGHS-2 and cPLA 2 mRNA involves nuclear transcription factors which work in concert to induce the transcription of mRNA for the above noted enzymes. Our studies using SN50, an inhibitor of NF-κB translocation to the nucleus, suggest that this transcription factor is involved in our model. NF-κB has been demonstrated to be involved in the induction of PGHS-2 by LPS in other cell types, including J774 macrophages 36 and human umbilical vein endothelial cells. 37 Both the ERK and p38 kinases are capable of activating NF-κB. 41 It is not clear whether one or both of these kinases activate NF-κB in this system or whether the effects are additive or synergistic. The existence and identity of other potential transcription factors which may be involved in this system remain to be elucidated.
A general scheme of the sequence of signaling events which lead to LPS stimulation of PGE 2 production in human microvessel-derived endothelial cells can be summarized from our work and that of others as follows. Serum-dependent interactions of the LPS molecule with the cell are responsible for the activation of a cascade of tyrosine and MAP kinases that ultimately leads to the activation of various nuclear transcription factors, including NF-κB. Enhanced transcription and translation of mRNA for PGHS-2 leads to increased mass of PGHS-2 enzyme within the cell. This increased enzymatic specific activity would be responsible for the enhanced formation of PGE 2 from the available pool of intracellular arachidonic acid present within the cell as the result of the constitutive turnover of arachidonic acid in the membrane. An enhanced activity of cPLA 2 within the cell may also participate in the process of accelerated PGE 2 formation. PKC activity was not demonstrated to be involved in the LPS-induced enhancement of PGE 2 production in human microvascular endothelial cells. Instead, a PKC isoform appears to be inhibiting the production of PGE 2 in LPS-stimulated cells. Thus, LPS enhancement of both a stimulating and a modulating set of signal transduction cascades is responsible for the net enhanced gene expression of the PGHS-2 system in human microvessel-derived endothelial cells.
